monovalent influenza subvirion vaccine, H7N7

The monovalent influenza subvirion vaccine, H7N7, is an inactivated, split-virus (subvirion) vaccine designed to provide protection against the H7N7 subtype of Influenza A virus. This vaccine is part of pandemic preparedness efforts, specifically targeting highly pathogenic avian influenza (HPAI) strains that have demonstrated the potential for zoonotic transmission to humans, such as the 2003 outbreak in the Netherlands. The vaccine is typically produced in embryonated chicken eggs, where the virus is harvested, inactivated (often using formalin or beta-propiolactone), and then disrupted with detergents to create a subvirion preparation containing the viral surface antigens. Its primary mechanism of action is the induction of neutralizing antibodies against the viral hemagglutinin (H7) and neuraminidase (N7) proteins. Clinical trials, often sponsored by the National Institute of Allergy and Infectious Diseases (NIAID), have evaluated the vaccine's safety and immunogenicity, including its performance in prime-boost strategies involving live attenuated influenza vaccines (LAIV).

Other names

monovalent influenza subvirion vaccine H7N7H7N7 inactivated influenza vaccineH-7N7 inactivated influenza vaccineH 7N7 inactivated influenza vaccineH7N7 subvirion vaccineH-7N7 subvirion vaccineH 7N7 subvirion vaccineH7N7 monovalent inactivated vaccineH-7N7 monovalent inactivated vaccineH 7N7 monovalent inactivated vaccineH7N7-MIVH-7N7-MIVH 7N7-MIV